The UK and US have announced a landmark trade agreement that will guarantee zero import taxes on British pharmaceutical exports going into the US market.
The Terms of the Pact
As part of the deal, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these key products will be held at zero for a timeframe of three years.
This deal comes after recent warnings to dramatically increase tariffs on patented drug imports, with potential rates floated reaching 100%.
"This agreement with the UK reinforces the worldwide climate for innovative medicines and introduces much-needed fairness to American-British pharmaceutical trade," a release noted.
Commercial Importance
Medicines represent one of the Britain's biggest goods shipped to the US, which is clearly the biggest buyer for leading companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK sold drugs totaling £11.1bn to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This deal protects work, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Key UK Commitments
The deal includes several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Last year, repayments exceeded twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the sector and the ministers over spending levels and NHS adoption.
The disagreement were intensified by claims that American customers were paying significantly more for the same drugs than patients in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or cancelled, while major expansions have been directed toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its total funding over the past decade.
